Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors
JNCI: Journal of the National Cancer Institute · 2024
DOI: 10.1093/jnci/djae008 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Chao Cao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Cancer Survivors, Peptide Fragments, Nutrition Surveys. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
N-terminal pro–brain natriuretic peptide (NT-proBNP) is a cardiac biomarker associated with the risk of heart failure and death in the general population, but it has not been explored in cancer survivors.
Methods
Using a US nationally representative sample of adults 20 years of age and older from the National Health and Nutrition Examination Survey from 1999 to 2004, this study compared NT-proBNP levels between adults without cancer (n = 12 574) and adult cancer survivors (n = 787). It examined the association of NT-proBNP with all-cause and cause-specific mortality among cancer survivors.
Results
Cancer survivors had higher NT-proBNP levels than adults without cancer (median [interquartile range] = 125.4 pg/mL [52.4-286.0] vs 43.2 pg/mL [20.3-95.0]). In particular, survivors of breast, prostate, and colorectal cancers had higher NT-proBNP levels than adults without cancer (multivariable-adjusted P < .05). In total, 471 survivors died (141 from cancer; 95 from cardiac disease) during a median follow-up period of 13.4 years (9393 person-years). Among cancer survivors, higher NT-proBNP levels were statistically associated with increased risks of all-cause death (hazard ratio [HR] = 1.31, 95% confidence interval [CI] = 1.18 to 1.46) and cardiac death (HR = 1.55, 95% CI = 1.21 to 2.00) but not with death from cancer (HR = 1.10, 95% CI = 0.92 to 1.32]). Higher NT-proBNP levels were associated with elevated overall mortality in survivors of prostate cancer (HR = 1.49, 95% CI = 1.22 to 1.81) and colorectal cancer (HR = 1.78, 95% CI = 1.00 to 3.16) (P = .169 for interaction). Nonlinear dose-response relationships were observed between NT-proBNP and mortality, with statistically significant relationships emerging above 125 pg/mL.
Conclusions
Cancer survivors had higher NT-proBNP levels than adults without cancer, and elevated NT-proBNP levels were associated with higher risks of all-cause and cardiac mortality in cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, AB, Canada.
- Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
ORCID-Profile: Chao Cao
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Cao, C., Yang, L., Nohria, A., Mayer, E. L., Partridge, A. H., & Ligibel, J. A. (2024). Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae008
Vancouver
Cao C, Yang L, Nohria A, Mayer EL, Partridge AH, Ligibel JA. Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae008
BibTeX
@article{Cao2024,
author = {Cao, Chao and Yang, Lin and Nohria, Anju and Mayer, Erica L and Partridge, Ann H and Ligibel, Jennifer A},
title = {Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
doi = {10.1093/jnci/djae008}
}
EUVIMED